Prospective, Multicenter, Open-Label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity in Subjects with Relapsed or Refractory Diffuse Large B-
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Jazz Pharmaceuticals
Start Date
October 17, 2019
End Date
March 16, 2021
Administered By
Duke Cancer Institute
Awarded By
Jazz Pharmaceuticals
Start Date
October 17, 2019
End Date
March 16, 2021